– VANTAA, Finland, November 13, 2015 /PRNewswire/ —
Promises to make screening for risk of osteoporosis simple, reliable and affordable 
Oscare Medical Oy announces that it will be demonstrating its unique low frequency ultrasound device, the OsCare Sono® for osteoporosis assessment, at this year’s Medica in Hall 16, booth E57. Medica, the world’s largest medical exhibition, will be held on 16th – 19th November in Düsseldorf, Germany.
Osteoporosis, a bone condition that incurs an increasing risk of fracture, is a rapidly increasing problem for aging societies. The dual energy X-ray method (DXA) is the gold-standard for confirming a diagnosis of osteoporosis, but the expense, and limited availability, of DXA make it an impractical technique for screening people at an increased risk for osteoporosis. By assessing bone strength from the forearm radial bone using ultrasound, the OsCare Sono® allows for safe and inexpensive assessment of an individual’s risk for osteoporosis.
OsCare Sono® measurements have been shown to correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting that the device uniquely offers enhanced sensitivity to early osteoporotic changes. Research also indicates that the OsCare Sono® can help identify people at an increased risk for osteoporosis and therefore those individuals who may benefit from further diagnostics.
A large 250-patient study is underway to determine how well OsCare Sono® measurements correlate with microstructural bone parameters as defined by high-resolution peripheral quantitative computed tomography. The ability of the Oscare Sono® to discriminate between individuals according to their fracture history is also being assessed as part of this study, led by Professor Serge Ferrari, Head of Department, Service of Bone Diseases at Geneva University Hospital, Switzerland.
About Oscare Sono®
The Oscare Sono® is a compact, hand-held device designed for osteoporosis risk assessment in clinics and low-threshold locations, such as high street pharmacies. The device attaches via a USB connector to a standard PC. A measurement is taken from the forearm over a few minutes using harmless ultrasound. An individual’s measurement is compared to the normal value observed in healthy young women, and the final Oscare Sono® result is ready within seconds for counseling.
About Oscare Medical
Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp which also markets the hugely successful Icare® tonometer product family. The Oscare Sono® is CE-marked and is on sale in several European countries. Oscare Medical is now rapidly expanding its distribution partner network. See: http://www.oscaremedical.com.
Contact:
Mervi Turunen Sales & Marketing Manager T: [email protected]